# Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01719003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01719003](<https://clinicaltrials.gov/study/NCT01719003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01719003

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1413 participants.

## Technical summary

Registry record NCT01719003. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2016-02-19.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1413 participants (enrolled count; ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Primary completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Results first posted: 2016-02-19 (ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Countries: United States; Brazil; Canada; Czechia; Egypt; France; Germany; Guatemala; Lebanon; Malaysia; Mexico; Peru; Philippines; Russia; Serbia; South Korea; Spain; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT01719003, source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01719003-2016-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Condition: Hyperglycemia
- Intervention (Drug): Metformin 500 mg bid
- Intervention (Drug): Metformin 1000 mg bid
- Intervention (Drug): Empagliflozin low dose qd
- Intervention (Drug): Empagliflozin high dose qd
- Intervention (Drug): Empagliflozin low dose bid
- Intervention (Drug): Metformin 500 mg bid
- Intervention (Drug): Empagliflozin high dose bid
- Intervention (Drug): Empagliflozin low dose bid
- Intervention (Drug): Metformin 1000 mg bid
- Intervention (Drug): Metformin 500 mg bid
- Intervention (Drug): Metformin 1000 mg bid
- Intervention (Drug): Empagliflozin high dose bid
- Intervention (Drug): Metformin 1000 mg bid
- Intervention (Drug): Empagliflozin high dose bid
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes (`cardio:pubmed-27493136`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 76c08d371e5fe0f584304524844563aed91fdbc8582dd85a03b744e23ca4ad21
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
